PI Industries Limited has informed the Exchange regarding a press release dated August 12, 2025, titled "Press release for the Quarter ended June 30, 2025".
PIIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
PI Industries reported Q1 FY26 consolidated revenue of Rs. 19,005 million, down ~8% YoY, dragged by an ~14% decline in Agchem Exports due to customer destocking and tariff-related supply chain disruptions. EBITDA fell ~11% YoY to Rs. 5,219 million with margins holding at 27%, and net profit slipped ~11% to Rs. 4,000 million, though gross margins expanded 565 bps to 57% on a favourable product mix. The pharma platform (PI Health Sciences) rebounded sharply with 186% YoY revenue growth, while domestic agri grew ~6% aided by a strong Kharif season and higher rice acreage; biologicals revenue dropped ~38% after an abrupt June 2025 industry-wide regulatory suspension. The company commercialised 4 new products in Q1 and filed India's first indigenous discovery molecule (Pioxaniliprole) for registration. Net cash stood at Rs. 41,554 million with operating cash flow of Rs. 2,168 million, and management guided to single-digit revenue growth for FY26 with sustained margins, expecting acceleration in H2 FY26.
Soft headline numbers in Q1 are likely already priced in, but the pharma rebound, strong cash balance, new product pipeline, and management's H2 acceleration guidance could provide modest support to the stock. Investors should watch for normalisation of biologicals sales, Agchem export destocking, and progress on the pharma CDMO ramp-up over coming quarters.